PD patients with diabetes who were treated with DPP4 inhibitors had (a) an increased baseline dopamine transporter availability in the anterior, posterior, and ventral putamen; (b) a slower increase in the required L-DOPA doses; and (c) a reduced rate of L-DOPA-induced dyskinesia [389]. This evidence concerns the gene SLC6A3 and Parkinson disease.